Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Trials
Published in: Trials 1/2020

Open Access 01-12-2020 | Irritable Bowel Syndrome | Study protocol

Does propolis affect the quality of life and complications in subjects with irritable bowel syndrome (diagnosed with Rome IV criteria)? A study protocol of the randomized, double-blinded, placebo-controlled clinical trial

Authors: Mahsa Miryan, Pezhman Alavinejad, Mohammadreza Abbaspour, Davood Soleimani, Alireza Ostadrahimi

Published in: Trials | Issue 1/2020

Login to get access

Abstract

Background

Irritable bowel syndrome (IBS) is one of the most frequent and recurrent gastrointestinal diseases. However, up to now, no pharmacological agent has been approved to treat IBS. Emerging evidence showed that inflammation has a vital role in enhancing nervous system sensitivity and perception of abdominal pain in subjects with IBS. Propolis is an herbal substance with a broad spectrum of antioxidants, anti-inflammatory, and prebiotic properties, which might exert beneficial effects to reduce the severity of IBS. The current clinical trial aims to evaluate the efficacy of propolis supplementation on IBS.

Methods

This single-center, randomized, double-blind, placebo-controlled clinical trial will be performed to evaluate the effect of propolis supplementation in adult patients with IBS diagnosed with Rome IV criteria. Fifty-two eligible patients will randomly be allocated to receive a propolis tablet (450 mg, containing 100 mg polyphenol compounds) or identical placebo, twice daily for 6 weeks. The primary outcome of the trial is an improvement in IBS severity from baseline to the sixth week of intervention. The secondary outcomes include the change in weight, waist circumference, and IBS quality of life. We will use the paired sample t test or Mann-Whitney U test for the within-group comparison and independent sample t test or Wilcoxon rank-sum and chi-square test or Fisher’s exact test for the between-group comparison. Besides, a multivariable-adjusted mean effect will be computed using the ANCOVA test.

Discussion

We hypothesize that propolis supplementation would be useful for treating IBS through its antioxidants, anti-inflammatory, and prebiotic properties. This trial will show the results of propolis supplementation, whether positive or negative, on IBS. If the current trial confirms our hypothesis, propolis supplementation can be a new choice in adjunctive therapy of IBS.

Trial registration

Iranian Registry of Clinical Trials IRCT20190708044154N1. Registered on 26 December 2019. Updated on 13 February 2020. https://​en.​irct.​ir/​trial/​40983

Sponsor

Tabriz University of Medical Sciences, Tabriz, Iran
Appendix
Available only for authorised users
Literature
1.
Kupfer SS, Jabri B. Pathophysiology of celiac disease. Gastrointest Endosc Clin. 2012;22(4):639–60.
2.
Kosako M, Akiho H, Miwa H, Kanazawa M, Fukudo S. Influence of the requirement for abdominal pain in the diagnosis of irritable bowel syndrome with constipation (IBS-C) under the Rome IV criteria using data from a large Japanese population-based internet survey. BioPsychoSocial Med. 2018;12(1):18.
3.
Bai T, Xia J, Jiang Y, Cao H, Zhao Y, Zhang L, et al. Comparison of the Rome IV and Rome III criteria for IBS diagnosis: a cross-sectional survey. J Gastroenterol Hepatol. 2017;32(5):1018–25.PubMed
4.
Ishihara S, Kawashima K, Fukuba N, Tada Y, Kotani S, Mishima Y, et al. Irritable bowel syndrome-like symptoms in ulcerative colitis patients in clinical remission: association with residual colonic inflammation. Digestion. 2019;99(1):46–51.PubMed
5.
Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1(2):133–46.PubMed
6.
Malani PN. Harrison’s principles of internal medicine. JAMA. 2012;308(17):1813–4.
7.
Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(22):6759.PubMedPubMedCentral
8.
Ng QX, Soh AYS, Loke W, Lim DY, Yeo W-S. The role of inflammation in irritable bowel syndrome (IBS). J Inflamm Res. 2018;11:345.PubMedPubMedCentral
9.
Akehurst R, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut. 2001;48(2):272–82.PubMedPubMedCentral
10.
Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010;59(3):325–32.PubMed
11.
Han K, Wang J, Seo J-G, Kim H. Efficacy of double-coated probiotics for irritable bowel syndrome: a randomized double-blind controlled trial. J Gastroenterol. 2017;52(4):432–43.PubMed
12.
Suzuki T, Hara H. Role of flavonoids in intestinal tight junction regulation. J Nutr Biochem. 2011;22(5):401–8.PubMed
13.
Sforcin JM. Biological properties and therapeutic applications of propolis. Phytother Res. 2016;30(6):894–905.PubMed
14.
Huang S, Zhang C-P, Wang K, Li GQ, Hu F-L. Recent advances in the chemical composition of propolis. Molecules. 2014;19(12):19610–32.PubMedPubMedCentral
15.
Wang K, Jin XL, Li QQ, Sawaya A, Le Leu RK, Conlon MA, et al. Propolis from different geographic origins decreases intestinal inflammation and bacteroides spp. Populations in a model of DSS-induced colitis. Mol Nutr Food Res. 2018;62(17):1800080.
16.
Mariano LNB, Arruda C, Somensi LB, Costa APM, Perondi EG, Boeing T, et al. Brazilian green propolis hydroalcoholic extract reduces colon damages caused by dextran sulfate sodium-induced colitis in mice. Inflammopharmacology. 2018;26(5):1283–92.PubMed
17.
Wang K, Jin X, You M, Tian W, Le Leu RK, Topping DL, et al. Dietary propolis ameliorates dextran sulfate sodium-induced colitis and modulates the gut microbiota in rats fed a western diet. Nutrients. 2017;9(8):875.PubMedCentral
18.
Sabuncuoglu M, Kismet K, Kilicoglu S, Kilicoglu B, Erel S, Muratoglu S, et al. Propolis reduces bacterial translocation and intestinal villus atrophy in experimental obstructive jaundice. World J Gastroenterol. 2007;13(39):5226–31.PubMedPubMedCentral
19.
El-Ghazaly MA, Rashed RR, Khayyal MT. Anti-ulcerogenic effect of aqueous propolis extract and the influence of radiation exposure. Int J Radiat Biol. 2011;87(10):1045–51.PubMed
20.
Roquetto AR, Monteiro NES, Moura CS, Toreti VC, de Pace F, Santos AD, et al. Green propolis modulates gut microbiota, reduces endotoxemia and expression of TLR4 pathway in mice fed a high-fat diet. Food Res Int. 2015;76(Pt 3):796–803.PubMed
21.
Wang K, Jin X, Chen Y, Song Z, Jiang X, Hu F, et al. Polyphenol-rich propolis extracts strengthen intestinal barrier function by activating AMPK and ERK signaling. Nutrients. 2016;8(5):272.PubMedCentral
22.
Karimian J, Hadi A, Pourmasoumi M, Najafgholizadeh A, Ghavami A. The efficacy of propolis on markers of glycemic control in adults with type 2 diabetes mellitus: a systematic review and meta-analysis. Phytother Res. 2019;33(6):1616–26.PubMed
23.
24.
Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395–402.PubMed
25.
Samadi N, Khosravi HM, Rahmanian M, Shahi MA. Effect of bee propolis supplementation on insulin resistance indices in patients with type 2 diabetes: a randomized double-blind clinical trial; 2017.
26.
Lee KN, Lee OY. Intestinal microbiota in pathophysiology and management of irritable bowel syndrome. World J Gastroenterol. 2014;20(27):8886.
27.
Mahan LK, Raymond JL. Krause's food & the nutrition care process-e-book. St. Louis: Elsevier Health Sciences; 2016.
28.
Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381–95.
29.
Moghaddam MB, Aghdam FB, Jafarabadi MA, Allahverdipour H, Nikookheslat SD, Safarpour S. The Iranian Version of International Physical Activity Questionnaire (IPAQ) in Iran: content and construct validity, factor structure, internal consistency and stability. World Appl Sci J. 2012;18(8):1073–80.
30.
Sjostrom M, Ainsworth B, Bauman A, Bull F, Hamilton-Craig C, Sallis J. Guidelines for data processing analysis of the International Physical Activity Questionnaire (IPAQ)-short and long forms; 2005.
31.
Beck AT, Steer R. Beck anxiety inventory (BAI). Überblick über Reliabilitäts-und Validitätsbefunde von klinischen und außerklinischen Selbst-und Fremdbeurteilungsverfahren; 1988. p. 7.
32.
Rafiei M, Seifi A. An investigation into the reliability and validity of beck anxiety inventory among the university students. Iran J Psychiatry Clin Psychol. 2013;7(27):37–46.
33.
Kaviani H, Mousavi A. Psychometric properties of the Persian version of Beck Anxiety Inventory (BAI). Tehran Univ Med J TUMS Publ. 2008;66(2):136–40.
34.
A'hern R. Sample size tables for exact single-stage phase II designs. Stat Med. 2001;20(6):859–66.PubMed
35.
Baştürk A, Artan R, Yılmaz A. Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: a randomized controlled trial. Turk J Gastroenterol. 2016;27(5):439–43.PubMed
36.
Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27.PubMedPubMedCentral
37.
Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380(8):711–9.PubMed
38.
Enders CK. A primer on maximum likelihood algorithms available for use with missing data. Struct Equ Model. 2001;8(1):128–41.
39.
Simone-Finstrom M, Borba R, Wilson M, Spivak M. Propolis counteracts some threats to honey bee health. Insects. 2017;8(2):46.PubMedCentral
40.
Batista LLV, Campesatto EA, Assis MLB, Barbosa APF, Grillo LAM, Dornelas CB. Comparative study of topical green and red propolis in the repair of wounds induced in rats. Rev Col Bras Cir. 2012;39(6):515–20.PubMed
41.
Silva LM, Souza PD, Jaouni SKA, Harakeh S, Golbabapour S, de Andrade SF. Propolis and its potential to treat gastrointestinal disorders. Evid Based Complement Alternat Med. 2018;2018:2035820.PubMedPubMedCentral
42.
43.
Niedzielska I, Puszczewicz Z, Mertas A, Niedzielski D, Różanowski B, Baron S, et al. The influence of ethanolic extract of Brazilian green propolis gel on hygiene and oral microbiota in patients after mandible fractures. Biomed Res Int. 2016;2016:9190814.PubMedPubMedCentral
44.
Aslan A, Temiz M, Atik E, Polat G, Sahinler N, Besirov E, et al. Effectiveness of mesalamine and propolis in experimental colitis. Adv Ther. 2007;24(5):1085–97.PubMed
45.
Abikim G, Yimit R, Tursunay A, Aerziguli T, Mutallip A. Effect of essential oils extracted from Xingjiang propolis on cell proliferation, cell cycle progression and apoptosis in human colorectal cancer cell line HTC-116. Shijie Huaren Xiaohua Zazhi. 2011;19:1469–75.
46.
Kassaian N, Aminorroaya A, Feizi A, Jafari P, Amini M. The effects of probiotic and synbiotic supplementation on metabolic syndrome indices in adults at risk of type 2 diabetes: study protocol for a randomized controlled trial. Trials. 2017;18(1):148.PubMedPubMedCentral
47.
48.
Khademolhosseini F, Mehrabani D, Nejabat M, Beheshti M, Heydari ST, Mirahmadizadeh A, et al. Irritable bowel syndrome in adults over 35 years in Shiraz, southern Iran: prevalence and associated factors. J Res Med Sci. 2011;16(2):200.PubMedPubMedCentral
Metadata
Title
Does propolis affect the quality of life and complications in subjects with irritable bowel syndrome (diagnosed with Rome IV criteria)? A study protocol of the randomized, double-blinded, placebo-controlled clinical trial
Authors
Mahsa Miryan
Pezhman Alavinejad
Mohammadreza Abbaspour
Davood Soleimani
Alireza Ostadrahimi
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Trials / Issue 1/2020
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/s13063-020-04615-5

Other articles of this Issue 1/2020

Trials 1/2020 Go to the issue

Study protocol

Evaluation of the effectiveness and tolerance of tetracosactide in the treatment of post-dural puncture headaches (ESYBRECHE): a study protocol for a randomised controlled trial

Study protocol

Effects of perioperative enhanced recovery after surgery pathway management versus traditional management on the clinical outcomes of laparoscopic-assisted radical resection of distal gastric cancer: study protocol for a randomized controlled trial

Research

Global mapping of randomised trials related articles published in high-impact-factor medical journals: a cross-sectional analysis

Update

Evaluating the efficacy and safety of GKT137831 in adults with type 1 diabetes and persistently elevated urinary albumin excretion: a statistical analysis plan

Review

Defining key design elements of registry-based randomised controlled trials: a scoping review

Study protocol

Different kinds of acupuncture treatments for knee osteoarthritis: a multicentre, randomized controlled trial